The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme ...
Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...
Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...
A research group led by Associate Professor Tetsuya Muramoto from the Faculty of Science, Toho University, has established a ...
A recent study utilizing cryo-EM advances our understanding of how bacterial immune systems function and reveals new aspects ...
A popular gene-editing technique may unintentionally delete and rearrange DNA bases, according to a new study published in Nature Biotechnology. The study involves the use of CRISPR-Cas9, a system ...
Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...
Two studies published in Nature Medicine June 11 contribute to a small body of literature suggesting cells edited with CRISPR-Cas9 may cause cancer. Here are five things to know about the studies and ...
Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results